File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Pulmonary toxicity in patients with non-Hodgkin's lymphoma treated with bleomycin-containing combination chemotherapy

TitlePulmonary toxicity in patients with non-Hodgkin's lymphoma treated with bleomycin-containing combination chemotherapy
Authors
Ngan, HYSLiang, RHSLam, WKChan, TK
Issue Date1993
PublisherSpringer. The Journal's web site is located at http://www.springer.com/medicine/oncology/journal/280
Citation
Cancer Chemotherapy And Pharmacology, 1993, v. 32 n. 5, p. 407-409 How to Cite?
DOI: http://dx.doi.org/10.1007/BF00735929
AbstractSubclinical and clinical bleomycin-induced pulmonary toxicity (BIP) were investigated retrospectively in 109 patients with non-Hodgkin's lymphoma treated by combination chemotherapy containing bleomycin. A decrease in carbon monoxide diffusing capacity (DLCO) was found in 12.8% of patients. The cumulative risk of abnormal DLCO increased with the increasing total cumulative dose of bleomycin. No significant difference in the rate of BIP was observed between patients receiving bleomycin/Adriamycin/cyclophosphamide/vincristine/prednisone (BACOP; bleomycin given at 10 mg/m2 for 4 weeks) and bleomycin/Adriamycin/cyclophosphamide/vincristine/dexamethasone/methot rexate/folinic acid (m-BACOD; bleomycin given at 4 mg/m2 for 3 weeks, methotrexate given at 200 mg/m2. Monitoring for subclinical BIP should be considered in patients with non-Hodgkin's lymphoma even if only a low dose of bleomycin was given in the presence of other chemotherapeutic agents.
Persistent Identifierhttp://hdl.handle.net/10722/161976
ISSN
0344-5704
2021 Impact Factor: 3.288
2020 SCImago Journal Rankings: 1.112
ISI Accession Number ID
WOS:A1993LM60900015

 

DC FieldValueLanguage
dc.contributor.authorNgan, HYSen_US
dc.contributor.authorLiang, RHSen_US
dc.contributor.authorLam, WKen_US
dc.contributor.authorChan, TKen_US
dc.date.accessioned2012-09-05T05:16:25Z-
dc.date.available2012-09-05T05:16:25Z-
dc.date.issued1993en_US
dc.identifier.citationCancer Chemotherapy And Pharmacology, 1993, v. 32 n. 5, p. 407-409en_US
dc.identifier.issn0344-5704en_US
dc.identifier.urihttp://hdl.handle.net/10722/161976-
dc.description.abstractSubclinical and clinical bleomycin-induced pulmonary toxicity (BIP) were investigated retrospectively in 109 patients with non-Hodgkin's lymphoma treated by combination chemotherapy containing bleomycin. A decrease in carbon monoxide diffusing capacity (DLCO) was found in 12.8% of patients. The cumulative risk of abnormal DLCO increased with the increasing total cumulative dose of bleomycin. No significant difference in the rate of BIP was observed between patients receiving bleomycin/Adriamycin/cyclophosphamide/vincristine/prednisone (BACOP; bleomycin given at 10 mg/m2 for 4 weeks) and bleomycin/Adriamycin/cyclophosphamide/vincristine/dexamethasone/methot rexate/folinic acid (m-BACOD; bleomycin given at 4 mg/m2 for 3 weeks, methotrexate given at 200 mg/m2. Monitoring for subclinical BIP should be considered in patients with non-Hodgkin's lymphoma even if only a low dose of bleomycin was given in the presence of other chemotherapeutic agents.en_US
dc.languageengen_US
dc.publisherSpringer. The Journal's web site is located at http://www.springer.com/medicine/oncology/journal/280en_US
dc.relation.ispartofCancer Chemotherapy and Pharmacologyen_US
dc.subject.meshAdolescenten_US
dc.subject.meshAdulten_US
dc.subject.meshAgeden_US
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols - Adverse Effects - Therapeutic Useen_US
dc.subject.meshBleomycin - Administration & Dosage - Adverse Effectsen_US
dc.subject.meshChi-Square Distributionen_US
dc.subject.meshCyclophosphamide - Administration & Dosage - Adverse Effectsen_US
dc.subject.meshDexamethasone - Administration & Dosage - Adverse Effectsen_US
dc.subject.meshDoxorubicin - Administration & Dosage - Adverse Effectsen_US
dc.subject.meshHumansen_US
dc.subject.meshLeucovorin - Administration & Dosage - Adverse Effectsen_US
dc.subject.meshLung - Drug Effects - Physiopathologyen_US
dc.subject.meshLymphoma, Non-Hodgkin - Drug Therapy - Physiopathologyen_US
dc.subject.meshMethotrexate - Administration & Dosage - Adverse Effectsen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshPrednisone - Administration & Dosage - Adverse Effectsen_US
dc.subject.meshPulmonary Diffusing Capacity - Drug Effectsen_US
dc.subject.meshRespiratory Function Testsen_US
dc.subject.meshRetrospective Studiesen_US
dc.subject.meshVincristine - Administration & Dosage - Adverse Effectsen_US
dc.titlePulmonary toxicity in patients with non-Hodgkin's lymphoma treated with bleomycin-containing combination chemotherapyen_US
dc.typeArticleen_US
dc.identifier.emailNgan, HYS:hysngan@hkucc.hku.hken_US
dc.identifier.emailLiang, RHS:rliang@hku.hken_US
dc.identifier.authorityNgan, HYS=rp00346en_US
dc.identifier.authorityLiang, RHS=rp00345en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1007/BF00735929-
dc.identifier.pmid7687934-
dc.identifier.scopuseid_2-s2.0-0027255433en_US
dc.identifier.volume32en_US
dc.identifier.issue5en_US
dc.identifier.spage407en_US
dc.identifier.epage409en_US
dc.identifier.isiWOS:A1993LM60900015-
dc.publisher.placeGermanyen_US
dc.identifier.scopusauthoridNgan, HYS=34571944100en_US
dc.identifier.scopusauthoridLiang, RHS=26643224900en_US
dc.identifier.scopusauthoridLam, WK=7203021937en_US
dc.identifier.scopusauthoridChan, TK=7402687762en_US
dc.identifier.issnl0344-5704-

Export via OAI-PMH Interface in XML Formats

OR

Export to Other Non-XML Formats